Response to McGirr Et Al.'s Comment on "Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada"

Overview

Journal Infect Dis Ther

Specialty Infectious Diseases

Date 2018 Nov 10

PMID 30411203

Citations 2

Authors

Michele R Wilson

Matt Wasserman

Taj Jadavji

Maarten Postma

Marie-Claude Breton

Francois Peloquin

Stephanie R Earnshaw

Cheryl McDade

Heather L Sings

Raymond Farkouh

Affiliations

Soon will be listed here.

Citing Articles

Response to Gomez et al.'s Letter to the Editor Regarding: "Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants".

Perdrizet J, Horn E, Nua W, Perez-Peralta J, Nailes J, Santos J Infect Dis Ther. 2022; 11(4):1763-1765.

PMID: 35575973 PMC: 9334460. DOI: 10.1007/s40121-022-00641-9.

Comment on Gomez et. al. "Response to article by Wasserman et. al. (2018) 'Modelling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico'".

Wasserman M, Palacios M, Grajales A, Wilson M, McDade C, Farkouh R Hum Vaccin Immunother. 2019; 15(3):572-574.

PMID: 30657407 PMC: 6988870. DOI: 10.1080/21645515.2018.1558691.

References

Caro J, Briggs A, Siebert U, M Kuntz K . Modeling good research practices--overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1. Med Decis Making. 2012; 32(5):667-77. DOI: 10.1177/0272989X12454577. View

van Hoek A, Choi Y, Trotter C, Miller E, Jit M . The cost-effectiveness of a 13-valent pneumococcal conjugate vaccination for infants in England. Vaccine. 2012; 30(50):7205-13. DOI: 10.1016/j.vaccine.2012.10.017. View

Domingues C, Verani J, Montenegro Renoiner E, Brandileone M, Flannery B, De Oliveira L . Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case-control study. Lancet Respir Med. 2014; 2(6):464-71. PMC: 9003592. DOI: 10.1016/S2213-2600(14)70060-8. View

Jokinen J, Rinta-Kokko H, Siira L, Palmu A, Virtanen M, Nohynek H . Impact of ten-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in Finnish children--a population-based study. PLoS One. 2015; 10(3):e0120290. PMC: 4364013. DOI: 10.1371/journal.pone.0120290. View

Dagan R, Pelton S, Bakaletz L, Cohen R . Prevention of early episodes of otitis media by pneumococcal vaccines might reduce progression to complex disease. Lancet Infect Dis. 2016; 16(4):480-92. DOI: 10.1016/S1473-3099(15)00549-6. View

Delgleize E, Leeuwenkamp O, Theodorou E, Van de Velde N . Cost-effectiveness analysis of routine pneumococcal vaccination in the UK: a comparison of the PHiD-CV vaccine and the PCV-13 vaccine using a Markov model. BMJ Open. 2016; 6(11):e010776. PMC: 5168567. DOI: 10.1136/bmjopen-2015-010776. View

Castiglia P, Pradelli L, Castagna S, Freguglia V, Palu G, Esposito S . Overall effectiveness of pneumococcal conjugate vaccines: An economic analysis of PHiD-CV and PCV-13 in the immunization of infants in Italy. Hum Vaccin Immunother. 2017; 13(10):2307-2315. PMC: 5647981. DOI: 10.1080/21645515.2017.1343773. View

Isturiz R, Sings H, Hilton B, Arguedas A, Reinert R, Jodar L . Streptococcus pneumoniae serotype 19A: worldwide epidemiology. Expert Rev Vaccines. 2017; 16(10):1007-1027. DOI: 10.1080/14760584.2017.1362339. View

Zhang X, Leeuwenkamp O, Oh K, Lee Y, Kim C . Cost-effectiveness analysis of infant pneumococcal vaccination with PHiD-CV in Korea. Hum Vaccin Immunother. 2017; 14(1):85-94. PMC: 5791581. DOI: 10.1080/21645515.2017.1362513. View

10.

Wasserman M, Sings H, Jones D, Pugh S, Moffatt M, Farkouh R . Review of vaccine effectiveness assumptions used in economic evaluations of infant pneumococcal conjugate vaccine. Expert Rev Vaccines. 2017; 17(1):71-78. DOI: 10.1080/14760584.2018.1409116. View

11.

Thorrington D, van Rossum L, Knol M, de Melker H, Rumke H, Hak E . Impact and cost-effectiveness of different vaccination strategies to reduce the burden of pneumococcal disease among elderly in the Netherlands. PLoS One. 2018; 13(2):e0192640. PMC: 5806887. DOI: 10.1371/journal.pone.0192640. View

12.

Desmet S, Verhaegen J, Van Ranst M, Peetermans W, Lagrou K . Switch in a childhood pneumococcal vaccination programme from PCV13 to PCV10: a defendable approach?. Lancet Infect Dis. 2018; 18(8):830-831. DOI: 10.1016/S1473-3099(18)30346-3. View

13.

Wasserman M, Lucas A, Jones D, Wilson M, Hilton B, Vyse A . Dynamic transmission modelling to address infant pneumococcal conjugate vaccine schedule modifications in the UK. Epidemiol Infect. 2018; 146(14):1797-1806. PMC: 9506701. DOI: 10.1017/S095026881800198X. View